These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 18173357)

  • 41. Shift of CMV-specific CD4+ T-cells to the highly differentiated CD45RO-CD27- phenotype parallels loss of proliferative capacity and precedes progression to HIV-related CMV end-organ disease.
    Bronke C; Jansen CA; Westerlaken GH; De Cuyper IM; Miedema F; Tesselaar K; van Baarle D
    Clin Immunol; 2007 Aug; 124(2):190-9. PubMed ID: 17556025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT.
    Tormo N; Solano C; Benet I; Nieto J; de la Cámara R; López J; Garcia-Noblejas A; Muñoz-Cobo B; Costa E; Clari MA; Hernández-Boluda JC; Remigia MJ; Navarro D
    Bone Marrow Transplant; 2011 Nov; 46(11):1437-43. PubMed ID: 21243030
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.
    Barabas S; Spindler T; Kiener R; Tonar C; Lugner T; Batzilla J; Bendfeldt H; Rascle A; Asbach B; Wagner R; Deml L
    BMC Immunol; 2017 Mar; 18(1):14. PubMed ID: 28270111
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation.
    Foster AE; Gottlieb DJ; Sartor M; Hertzberg MS; Bradstock KF
    Biol Blood Marrow Transplant; 2002; 8(9):501-11. PubMed ID: 12374455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27- T cells in HIV-1-infected children.
    Bekker V; Bronke C; Scherpbier HJ; Weel JF; Jurriaans S; Wertheim-van Dillen PM; van Leth F; Lange JM; Tesselaar K; van Baarle D; Kuijpers TW
    AIDS; 2005 Jul; 19(10):1025-34. PubMed ID: 15958833
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients.
    Pipeling MR; John ER; Orens JB; Lechtzin N; McDyer JF
    J Infect Dis; 2011 Dec; 204(11):1663-71. PubMed ID: 22021622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV patients on antiretroviral therapy have high frequencies of CD8 T cells specific for Immediate Early protein-1 of cytomegalovirus.
    Stone SF; Price P; Khan N; Moss PA; French MA
    AIDS; 2005 Mar; 19(6):555-62. PubMed ID: 15802973
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid generation of CMV pp65-specific T cells for immunotherapy.
    Bao L; Sun Q; Lucas KG
    J Immunother; 2007; 30(5):557-61. PubMed ID: 17589296
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytotoxic polyfunctionality maturation of cytomegalovirus-pp65-specific CD4 + and CD8 + T-cell responses in older adults positively correlates with response size.
    Chiu YL; Lin CH; Sung BY; Chuang YF; Schneck JP; Kern F; Pawelec G; Wang GC
    Sci Rep; 2016 Jan; 6():19227. PubMed ID: 26778409
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects.
    Komanduri KV; Donahoe SM; Moretto WJ; Schmidt DK; Gillespie G; Ogg GS; Roederer M; Nixon DF; McCune JM
    Virology; 2001 Jan; 279(2):459-70. PubMed ID: 11162802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytomegalovirus (CMV)-specific CD8+ T cells in individuals with HIV infection: correlation with protection from CMV disease.
    Stone SF; Price P; French MA
    J Antimicrob Chemother; 2006 Apr; 57(4):585-8. PubMed ID: 16504998
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis.
    Walmsley SL; Raboud J; Angel JB; Mazzulli T; Shen S; Casciaro L; Young CD; Moussa G; Gough K; Rachlis A; Hopkins J
    HIV Clin Trials; 2006; 7(1):1-9. PubMed ID: 16632459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection.
    Pipeling MR; West EE; Osborne CM; Whitlock AB; Dropulic LK; Willett MH; Forman M; Valsamakis A; Orens JB; Moller DR; Lechtzin N; Migueles SA; Connors M; McDyer JF
    J Immunol; 2008 Jul; 181(1):546-56. PubMed ID: 18566421
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
    Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
    HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control.
    Popescu I; Pipeling MR; Shah PD; Orens JB; McDyer JF
    J Immunol; 2014 Dec; 193(11):5709-5722. PubMed ID: 25339676
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.
    Paine A; Oelke M; Tischer S; Heuft HG; Blasczyk R; Eiz-Vesper B
    J Immunother; 2010 Jan; 33(1):60-72. PubMed ID: 19952955
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells.
    Melenhorst JJ; Solomon SR; Shenoy A; Hensel NF; McCoy JP; Keyvanfar K; Barrett AJ
    J Immunother; 2006; 29(4):436-43; discussion 365-6. PubMed ID: 16799339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals.
    Sinclair E; Black D; Epling CL; Carvidi A; Josefowicz SZ; Bredt BM; Jacobson MA
    Viral Immunol; 2004; 17(3):445-54. PubMed ID: 15357911
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope.
    Ohnishi M; Sakurai T; Heike Y; Yamazaki R; Kanda Y; Takaue Y; Mizoguchi H; Kawakami Y
    Br J Haematol; 2005 Nov; 131(4):472-9. PubMed ID: 16281937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of cytomegalovirus (CMV)-specific T-cell immunity for the assessment of the risk of active CMV infection in non-immunosuppressed surgical and trauma intensive care unit patients.
    Clari MA; Aguilar G; Benet I; Belda J; Giménez E; Bravo D; Carbonell JA; Henao L; Navarro D
    J Med Virol; 2013 Oct; 85(10):1802-10. PubMed ID: 23868746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.